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Background: There is emerging evidence that the prevalence of exercise-induced 
bronchospasm (EIB) is significantly under-reported in many sports. There is little known 
about the potential performance improvement that may exist when sports players are 
detected and treated for EIB.  
Methods: Semi-professional rugby union players with no previous history of asthma 
volunteered to participate in the study. Each player performed the rugby football union 
(RFU) fitness test and completed a eucapnic voluntary hyperpnoea (EVH) challenge at 
baseline and 12 weeks later. A player with a positive EVH result was prescribed 
beclomethasone inhaler (200 µg; two puffs per day) for 12 weeks. Players with a negative 
EVH test were randomly allocated to either a placebo inhaler group or acted as controls.  
Results: Twenty nine rugby union players (mean ± SD; age 22.1± 4.2 years; body mass 
100.1± 6.9 kg; stature 1.84± 0.07 m) were recruited. Seven players (24% of total) had a 
positive EVH challenge with a mean decrease in FEV1 of -13.6 ±3.5 % from baseline. 
There was no significant group difference (P=0.359) in performance improvement of the 
RFU fitness test between the EVH positive group (mean Δ: -22.3 seconds; 8.0 ± 2.8% 
improvement), placebo group (mean Δ: -16.5 seconds; 6.7 ± 1.6% improvement), and 
controls (mean Δ: -12.2 seconds; 5.7 ± 3.5% improvement). 
Conclusion: Prevalence of EIB in semi-professional rugby union players was 24%. A 12-
week prescription of beclomethasone (200 µg) showed similar improvements in RFU 
fitness test performance in players diagnosed with EIB compared to players with healthy 
airway responsiveness.   






Exercise-induced bronchoconstriction (EIB) is closely related to asthma and is defined as 
a transient narrowing of the airways limiting expiration that usually follows a bout of 
exercise, and is reversible spontaneously or through inhalation of β2-agonists (Anderson, 
1997). Emerging evidence has demonstrated that susceptible athletes do not recognise 
they have EIB (Lund et al., 2009; Rundell et al., 2001; Dickinson et al., 2005; 2011). 
Without the intervention of screening programmes, athletes may remain undiagnosed and 
may continue to suffer from EIB potentially compromising performance and health (Holzer 
and Brukner 2004; Dickinson et al 2011). The risk of acute bronchoconstriction in athletes 
can be reduced through early detection of EIB and suitable treatment (Carlson et al., 
2008). Diagnosis of EIB should incorporate a medical consultation and an indirect airway 
challenge. The inclusion of an indirect airway challenge is crucial as diagnosing EIB 
through symptoms alone can result in a higher prevalence of false positives (Rundell et 
al., 2002; Ansley et al. 2012). The eucapnic voluntary hyperpnoea (EVH) indirect airway 
challenge has a high level of sensitivity and specificity for the identification of EIB (Holzer 
et al., 2003), and is a suitable airway challenge in athletic populations (Dickinson et al., 
2006). 
The proposed mechanism for the development of EIB is a dehydration of the airway 
surface liquid caused by the inhalation of large volumes of ‘unconditioned’ air requiring 
humidification by the lower airways. The dehydration of the ASL causes an osmotic effect 
that leads to an inflammatory response causing bronchoconstriction (Anderson and 
Kippelen 2008). It is possible that if the inflammatory process is not controlled it may lead 
to damage of the epithelium and resultant airway remodelling. Hence sports that have 
high minute ventilation demands and take place in cold, dry environments are at risk of 
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airway damage and EIB development. It is crucial therefore that EIB is detected as early 
as possible in order to control airway inflammation and minimise the potential for airway 
remodelling. Rugby union is a sport that requires bouts of high minute ventilation and can 
take place in cold and dry environments. Therefore players can put themselves at 
increased risk of EIB and EIB development through training and game play. The dry 
environments encountered either at cold temperatures or at altitude accompanied by high 
ventilatory requirements could increase the risk of an acute episode of EIB in susceptible 
rugby players (Helenius et al., 1998). Despite a number of studies reporting a high 
prevalence of EIB in athletes whose sports take place in cold environments (Helenius et 
al. 1998; Rundell et al. 2001), there is limited data available investigating the prevalence 
of EIB in rugby union players.  
Once diagnosis of EIB has been made the most appropriate prevention strategy has been 
shown to incorporate regular use of inhaled corticosteroids (O'Byrne et al., 2001; Pauwels 
et al., 2003; Boushey et al., 2005). However, it is unclear whether detection of athletes 
with previously undiagnosed EIB and appropriately treating them with inhaled 
corticosteroid therapy results in an improvement in health and performance (Holzer et al., 
2007). At present there are no studies that have investigated the longer-term impact on 
health and performance of treating athletes with an initial diagnosis of EIB. Accordingly 
the aim of our study is two-fold: 1) to investigate the prevalence of EIB in rugby union 
players; 2) investigate the impact of corticosteroid therapy on airway function of 
susceptible rugby union players and how this impacts on a rugby-specific performance 




Forty semi-professional male rugby players from the same club in Northern England were 
approached to participate in the study. All participants agreeing to participate in the study 
provided written informed consent and ethical approval was provided by Leeds 
Metropolitan University. All tests were performed during pre-season training. Inclusion 
and exclusion criteria for the study are outlined in Table 1.  
 




Member of the same rugby union club  Recent chest infection (less than four 
weeks prior to testing) 
Male A current diagnosis of asthma and/or EIB 
and using inhaler therapy. 
Age: 18-30 years FEV1 of <70% predicted value at baseline 
spirometry. 
 Participants with injuries which will 




The Rugby Football Union (RFU) fitness test 
The RFU fitness test (157) was conducted by all participants (Figure 1). The test was 
familiar and was conducted regularly as part of routine training and fitness assessments. 
The RFU fitness test is similar to the 20m multi-stage fitness test (158), involving a number 
of timed repeated sprints. There are two different RFU fitness tests dependent on whether 
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the player is a forward or back, and participants completed the test according to their 















Figure 1: The RFU fitness test for forwards (left panel) and backs (right panel) 
 
EVH challenge 
All participants performed an EVH challenge within the same week as the fitness test (81). 
Maximal flow volume loops were recorded using a digital spirometer (ML3500 Micro 
Medical Spirometer, Cardinal Health, UK). The European Community for Coal and Steel 
(ECCS) reference values were used to predict maximal lung flow-volumes (160). All 
maximal flow-volume manoeuvres were performed in accordance with the European 
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Respiratory Society criteria (Miller et al 2005). Prior to the EVH challenge participants 
completed three maximal-flow volume manoeuvres. The best FEV1 was recorded and 
taken as baseline lung function. Other measurements collected included forced vital 
capacity (FVC), peak expiratory flow (PEF), and mid-expiratory flow rate at 50% of FVC 
(FEF50). 
The EVH challenge was carried out in accordance with methods outlined by Anderson et 
al. (2001) (84). During the EVH challenge each participant was asked to achieve target 
minute ventilation ( E) of 85% of the maximal voluntary ventilation (MVV) for six minutes. 
Target E was calculated by multiplying the baseline FEV1 by 30 (Anderson et al. 2001). 
The gas inhaled during the EVH challenge consisted of 74% nitrogen, 21% oxygen, and 
5% carbon dioxide. At the point of air entering the mouth the gas temperature was 18⁰C 
and humidity <2%. During the EVH challenge verbal encouragement and visual feedback 
was provided. Upon completion of the EVH challenge, two maximal flow volume loops 
were recorded at 3, 5, 7, 10 and 15 minutes. At each time point the flow volume loop with 
the best FEV1 was recorded and used to calculate the decrease from the baseline FEV1 
at each time point. If FEV1 was >10% from baseline at two consecutive time points this 
was deemed a positive EVH challenge. If participants presented with two consecutive 
time points where FEV1 fell >10% from baseline they were offered 200 μg of inhaled 
salbutamol and a repeat flow volume loop was measured 10 minutes after inhalation. All 
participants were asked to remain in the laboratory until their FEV1 was within 10% of the 
baseline measure. 
Participants were diagnosed with EIB if:  
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 They had a fall in FEV1 >10% from baseline at two consecutive time points 
following the EVH challenge.  
 The participant had an initial low-normal FEV1 (70-80% of predicted value at 
baseline spirometry with persistent respiratory symptoms. Following the EVH 
challenge there was a minimal decrease in the percentage of the FEV1, yet following 
use of a salbutamol inhaler there was an improvement of >12% from the baseline 
FEV1. 
 Each decision about a participant being diagnosed with EIB was taken in 
consultation with the club’s team doctor.  
A participant was deemed to be EVH negative if the FEV1 did not demonstrate a drop of 
≥10% on two consecutive time points.  
Randomisation of participants 
All players diagnosed with EIB were prescribed beclomethasone inhaler 200µg (two puffs 
per day). The negative EVH group was randomly selected to either receive a placebo 
inhaler to be used twice daily or they formed part of the control group that received no 
treatment. Both groups were shown how to use the inhaler by the club doctor. All 
participants completed their regular pre-season exercise training regimens. After twelve 
weeks, all players underwent re-assessment of the RFU fitness test under identical 
conditions. The EVH challenge was repeated in players with a positive diagnosis for EIB. 
Data Analysis 
Continuous variables are presented as mean and standard deviation (SD); categorical 
variables are reported as percentages. A one-way analysis of variance (ANOVA) was 
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used to identify baseline differences between groups. A repeated measures ANOVA with 
Bonferroni post hoc adjustment was used to identify differences over time (baseline to 12 
weeks). An arbitrary level of 5% statistical significance (two-tailed) was assumed. SPSS 
software v17.0 (IBM, NY, USA) was used to analyse the data.   
Results 
29 semi-professional rugby union players (mean ± SD; age 22.1 ± 4.1 years; stature 1.84 
± 0.07 m, body mass 100.1 ± 12.3 kg) agreed to participate in the study. There were no 
baseline differences in age, stature, and body mass between players with positive and 
negative EVH results (Table 2). The baseline RFU fitness test was completed by 24 
participants; however, due to injury and/or illness, only 16 participants completed both the 
baseline and 12 week post intervention RFU fitness tests.  
Table 2: Player characteristics separated by positive and negative EVH results at 
baseline 
Characteristic EVH positive (n=7) EVH negative (n=22) 
Age (years) 22.6 ± 3.8 22.0 ± 4.4 
Height (m) 1.87 ± 6.3 1.83 ±7.0 
Weight (kg) 101.9 ± 11.2 99.6 ±12.8 
FEV1 (l) 4.5±0.7 5.0±0.7 0.76 
Percent of predicted 
FEV1 
94.3±11.1 109.0±11.0 0.01 
FVC (l) 5.8±0.9 6.0±0.9 0.670 
PEF (l/min) 601.9± 69.8 640.7± 88.3 0.299 
FEF50 (l/min) 4.3 ±0.8 5.8±1.4 0.12 
Max FEV1 decrease 
post EVH challenge 
-11.6 ± 4.6 -6.0±3.6 0.002 
 
All 29 players completed the EVH challenge. None of the 29 participants had a previous 
diagnosis of asthma or EIB. Seven players (24%) were diagnosed with EIB. Of these, five 
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had a positive EVH challenge and two presented with significant reversibility following 
inhalation of salbutamol. Three other participants demonstrated a fall in FEV1 of >10%, 
but only at one time point. There was no significant difference in the baseline maximal 
flow volume measures between players with positive and negative EVH challenges. 
However, the baseline percentage of predicted FEV1 was significantly higher in the 
players with negative results (P=0.01). Seven participants (24%) were diagnosed with 
EIB. The maximal decrease in FEV1 was significantly (P=0.002) higher in the EVH 
positive group (Table 2). There was no significant relationship between the percentage of 
MVV achieved and the maximum FEV1 fall post EVH challenge (P=0.74) (Figure 2). 
Figure 3 illustrates the individual percentage decrease in FEV1 in players with positive 




Figure 2: Percentage of MVV achieved during the EVH challenge and the percentage 




Figure 3: Changes in FEV1 in rugby union players with positive and negative responses 
to the EVH challenge 
 
RFU Fitness Test 
Sixteen out of twenty-four players completed the baseline and 12 week follow up RFU 
fitness test. All three groups, EIB positive, placebo and control improved their fitness test 
scores after 12 weeks of training (P=0.014).When taken on an individual basis, all 
participants improved their RFU fitness test performance times over the 12 week period. 
There was no significant group difference (P=0.359) in performance improvement of the 
RFU fitness test between the EVH positive group (mean Δ: -22.3 seconds; 8.0 ± 2.8% 
improvement), controls (mean Δ: -12.2 seconds; 5.7 ± 3.5% improvement), and the 
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placebo group (mean Δ: 16.5 seconds; 6.7 ± 1.6% improvement) (Figure 4). A second 
EVH test was repeated after 12 weeks in players with an initial diagnosis of EIB. A 
decrease in FEV1 of >10% continued to remain in all players following the treatment 
period. 
 
Figure 4: Comparison of the mean time taken to complete the RFU fitness test at 
baseline and after the 12-week intervention for players with a positive EVH test, placebo 










This is the first study to screen a team of rugby union players for EIB and track changes 
in performance in those detected with EIB with no previous diagnosis. Our study shows 
that the prevalence of EIB in rugby union players with no previous history of asthma is 
24%. Following 12-week inhalation of prescribed beclomethasone (200µg) the EIB group 
showed significant improvement in the RFU fitness test. Although the EIB positive group 
significantly improved their RFU fitness performance from baseline they did not improve 
at a significantly greater rate than the placebo group or controls. The EIB group 
demonstrated the greatest fitness improvement over the intervention and our findings are 
similar to previous data from asthmatics recruited to a six-week treatment programme 
with inhaled corticosteroids (74)  
The high airway resistance that occurs during EIB increases the expiratory flow limitation 
during exercise (161) predisposing athletes to hypoxaemia during exercise.  Haverkamp 
(2005) found a significant decrease in arterial oxygen saturation during exercise caused 
by an increased difference in alveolar to arterial PO2 pressure and an insufficient 
ventilatory response resulting in reduced exercise performance.(72) Six weeks of inhaled 
corticosteroids increased arterial blood oxygen saturation during exercise and exercise 
performance in asthmatics (Haverkamp, 2005). It is hypothesised that had we not treated 
the EIB group they may have had impaired adaptation in fitness over the 12 weeks of 
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training. Due to ethical issues surrounding not treating an athlete for EIB once a diagnosis 
has been made we are unable to test this hypothesis in our study. 
The EVH challenge identified 24% of rugby union players with underlying EIB. This is 
similar to previous findings by Dickinson et al. (2011) where 32% of rugby players were 
found to have undiagnosed EIB (12). There is the potential for EIB to develop in an athlete 
following over exposure during training and competition to high ventilatory demands, dry 
air, or poor air quality. It may take several years for EIB to develop in susceptible 
individuals. Our group of rugby players were relatively young (22.6 years). It may be if we 
had an older group of rugby players the number of EIB positive athletes we detected may 
have been greater and similar to the report by Dickinson et al. (2011) (12). 
We found that the maximal flow volume measures at baseline did not distinguish between 
players with positive and negative results. FEV1 is commonly used to help diagnose 
intrinsic asthma, as it measures the expiratory flow at high and mid-lung volumes. The 
baseline FEV1 was within the normal range for all participants (>80% of the predicted 
FEV1), hence identification of undiagnosed EIB through analysis of the resting FEV1 (pre-
exercise) was not possible. This is supported by previous findings (Dickinson et al. 2005, 
2011) (12,87). The exception to this is the % predicted FEV1 obtained at baseline. Players 
with a positive diagnosis of EIB had significantly lower (P=0.011) % predicted FEV1 values 
compared to healthy controls at baseline. This result is similar to studies conducted on 
large cohorts of elite athletes that report EIB athletes to have significant lower % of 
predicted FEV1 measures (Dickinson 2005; 2011). It is difficult to distinguish players with 
a positive EVH test by analysis of the % predicted FEV1 as values are still within the 
normal range (>80% predicted value). Beck and colleagues (1994) demonstrated that 
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baseline spirometry in an athletic population was >20% higher than the predicted values 
for the general population. Future studies should determine an adjusted ‘normal range’ 
for high performance athletes (which may require further sub-specialisation for sporting 
mode i.e. power vs endurance sports). 
In our study, the players diagnosed with EIB were treated with inhaled corticosteroids as 
per the British Thoracic Society Guidelines (108), with inhaled beclomethasone, as this was 
found to improve EIB (74). The option of providing the EIB positive participants with solely 
β2-agonists was not feasible, as although β2-agonists can inhibit mast cell mediator 
release, this response is susceptible to desensitisation, a process that can be inhibited 
by corticosteroids. Corticosteroids can increase the transcription of the β2-receptor gene 
in the lung and the nasal mucosa. This effect of corticosteroids lessens the reduction in 
transcription of the β2-receptors, which would occur as a result of long term β2-agonist 
administration (163). However, when players with positive results for EIB underwent a 
repeated EVH challenge after 12 weeks of treatment, all participants still demonstrated a 
decrease in FEV1 >10%. Thus, other treatment options including fluticasone (138) or 
leukotrienes may require further consideration, although the latter is not considered a 
first-line treatment for EIB (147).  
 
There does not appear to be a relationship between respiratory symptoms and the 
presence/absence of EIB. Rundell and co-workers (2001) showed that in athletes 
experiencing a decrease of ≥10% in FEV1 post exercise challenge, respiratory symptoms 
were reported by 39% of athletes. Conversely, in athletes with EIB, respiratory symptoms 
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were reported by 41%. We found a similar trend in our study; 76% of the rugby players 
without EIB experienced respiratory symptoms, whilst 71% of the players with EIB denied 
any respiratory symptoms. This finding adds weight to previous studies which indicates 
that the analysis of signs and symptoms is not reliable method of diagnosing or rejecting 
EIB (76). Thus diagnosis of EIB must include an objective test of airway function alongside 
a medical consultation. 
Limitations 
Our study cohort presented with mild bronchoconstriction following the EVH challenge 
(decrease in FEV1 from baseline between 10-25%). We may have seen larger 
performance gains by using a group of athletes with moderate to severe EIB. In addition, 
the field-based assessment (RFU fitness test) whilst being ecologically valid and familiar 
to the rugby players, was less well controlled than a laboratory testing environment.  The 
EVH challenge is a highly sensitive and specific test for the diagnosis of underlying EIB 
(82). However the humidity of the air (2%) is much lower than any athlete is likely to inhale 
during most sporting situations. Occasionally, this may lead to over-cautious diagnosis of 
EIB where the impact of inhaled medication may be less significant.   
 
Conclusion: 
Prevalence of EIB in semi-professional rugby union players was 24%. A 12-week 
prescription of beclomethasone (200µg) showed similar improvements in RFU fitness test 
performance in players diagnosed with EIB compared to players with healthy airway 
responsiveness.   
 18 
 
What is already known? 
 Screening athletes with an indirect airway challenge such as EVH testing may 
result in diagnosis of EIB in previously undiagnosed athletes 
 
What this study adds? 
 The prevalence of EIB in UK-based rugby union players was 24% 
 Diagnosing EIB in rugby union players with no previous history and treating them 
with inhaled corticosteroids for 12 weeks allows them to make similar performance 
gains as players with healthy airway responsiveness.   
 
